Medytox Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
712
- Stock Symbol
-
086900
- Investments
-
11
- Share Price
-
$158.38
- (As of Thursday Closing)
Medytox General Information
Description
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
Contact Information
- 626 Teheran-ro
- Daechi-dong, Medytox Building
- Seoul, Gangnam-gu
- South Korea
Medytox Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $158.38 | $163.98 | $89.09 - $238.82 | $1.07B | 6.73M | 97.2K | $1.22 |
Medytox Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,289,975 | 698,806 | 743,870 | 975,823 |
| Revenue | 155,946 | 150,989 | 161,399 | 119,275 |
| EBITDA | 27,094 | 51,334 | 131,257 | (16,689) |
| Net Income | 8,596 | 28,643 | 82,200 | (25,050) |
| Total Assets | 457,207 | 472,154 | 485,453 | 428,780 |
| Total Debt | 62,447 | 95,702 | 111,693 | 135,125 |
Medytox Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medytox Comparisons
Industry
Financing
Details
000000
000000
Medytox Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | 00000 | 00.000 | 000000000000 | 00.000 |
| 0000000000 0000000 | Formerly VC-backed | Malvern, PA | 0 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000 | Corporation | Trevose, PA | 000 | 00.000 | 0000000000. | |
| 0000000000 0000000 | Corporation | San Francisco, CA | 000 | 000000&0 | ||
| 00000000 | Formerly VC-backed | Jersey City, NJ | 00 | 00000 | 00000000 | 00000 |
Medytox Patents
Medytox Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4265639-A2 | Anti-hvem antibody, and composition and method associated with same | Pending | 15-Dec-2020 | 00000000000 | |
| EP-4206226-A1 | Anti-vegf hexameric antibody and composition comprising same | Pending | 31-Aug-2020 | 000000000 | |
| CA-3190320-A1 | Heterodimeric fc fusion protein, and composition, use, and method related to same | Pending | 29-Jul-2020 | 0000000000 | |
| EP-4190806-A1 | Heterodimeric fc fusion protein, and composition, use, and method related to same | Pending | 29-Jul-2020 | 0000000000 | |
| US-20230256064-A1 | Cancer therapeutic agent | Pending | 23-Jul-2020 | A61K38/4893 |
Medytox Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jung Hyun-Ho Ph.D | Chief Executive Officer |
Medytox Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Medytox Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medytox Investments & Acquisitions (11)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aigen Sciences | 04-Oct-2022 | 0000 00000 | 000 | Drug Delivery | |
| Lysentech | 22-Dec-2021 | 00000 0000 | 00.000 | Drug Discovery | |
| Evolus | 01-Sep-2021 | 000000000 | Pharmaceuticals | ||
| Cellapeutics Bio | 28-Jul-2021 | 0000 00000 | Biotechnology | ||
| Novelty Nobility | 30-Jan-2020 | Early Stage VC | 00.000 | Drug Discovery |
Medytox Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Medytox Venture Investment | Venture Capital | Seoul, South Korea | 0000 |
Medytox ESG
Risk Overview
Risk Rating
Updated December, 02, 2022
29.89 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
